1. Home
  2. SACH vs RFL Comparison

SACH vs RFL Comparison

Compare SACH & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

N/A

Current Price

$1.10

Market Cap

48.6M

Sector

Real Estate

ML Signal

N/A

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

N/A

Current Price

$1.50

Market Cap

61.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
SACH
RFL
Founded
2010
2017
Country
United States
United States
Employees
29
N/A
Industry
Real Estate Investment Trusts
Real Estate
Sector
Real Estate
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
48.6M
61.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
SACH
RFL
Price
$1.10
$1.50
Analyst Decision
Hold
Analyst Count
3
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
119.3K
91.0K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
18.35%
N/A
EPS Growth
N/A
28.28
EPS
N/A
N/A
Revenue
N/A
$917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.96
52 Week Low
$0.80
$1.12
52 Week High
$1.35
$3.19

Technical Indicators

Market Signals
Indicator
SACH
RFL
Relative Strength Index (RSI) 69.13 65.63
Support Level $1.04 $1.41
Resistance Level $1.13 $1.63
Average True Range (ATR) 0.03 0.10
MACD 0.01 0.02
Stochastic Oscillator 80.51 71.25

Price Performance

Historical Comparison
SACH
RFL

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: